Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1181-1182, 2007; 10.1373/clinchem.2007.086611
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gundry, R. L.
Right arrow Articles by Van Eyk, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gundry, R. L.
Right arrow Articles by Van Eyk, J. E.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:1181-1182.)
© 2007 American Association for Clinical Chemistry, Inc.

Editorials

Unraveling the Complexity of Circulating Forms of Brain Natriuretic Peptide

Rebekah L. Gundry and Jennifer E. Van Eyka

Department of Medicine, Johns Hopkins University, Baltimore, MD

aAddress correspondence to this author at: 602 Mason F. Lord Bldg., Center Tower, 5200 Eastern Ave., Baltimore, MD 21224. Fax 410-550-8512; e-mail jvaneyk1@jhmi.edu.

The first 20% of the full text of this article appears below.

Determining the circulating form of a biomarker is critical for the development of a highly sensitive and specific immunoassay. The hormone brain natriuretic peptide (BNP) is produced in the atria as a preprohormone, and the cleavage of its signal sequence produces the circulating prohormone proBNP (amino acid residues 1–108, human sequence). The prohormone is subsequently cut to yield a 76-amino acid N-terminal (NT) fragment (NT-proBNP) and the 33-amino acid active hormone BNP (comprising residues 77–108 of proBNP). The 2 commercially available immunoassays detect either the circulating NT fragment or BNP and, potentially, could detect proBNP. However, whether these assays detect all possible circulating forms of BNP remains unclear.

The potential circulating forms of BNP have different intrinsic physical characteristics that can dictate antigenicity, extent of nonspecific binding during isolation, endogenous clearance kinetics, circulating half-life, and/or affinity for other proteins including cellular receptors and putative serum/plasma carrier proteins. Consequently, characterization of the physical status of each circulating form of BNP is key to assay development. It is critical to determine whether the circulating BNP forms have posttranslational modifications (PTM), such as phosphorylation or N- and O-linked glycosylation, and/or bind to other protein(s). In a recent issue of Clinical Chemistry, an article by Seferian et al. (1) described 2 approaches to shedding light on the circulating forms of BNP. The 2 strategies examined differences in (a) antigenicity, (b) antibody binding, and (c) the theoretical and observed MWs of the unmodified recombinant form and the circulating endogenous form(s). The data presented indicated that the chemistry of circulating BNP is complex. This complexity needs to be taken into account during immunoassay development.

Is there a potential PTM? Seferian et al. (1) produced a large number of peptides and fragments . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.